Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Tesla Raises Cybertruck Prices by $5,000 in US 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Add as a preferred source on Google
PHILADELPHIA, May 01, 2018 -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, May 8, 2018, at 8:30 a.m. ET to discuss corporate and financial results for the first quarter that ended March 31, 2018, and recent business highlights.
The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international), and entering passcode 1483429. To access a live audio webcast, please visit the “Investors” section at www.sparktx.com.
A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 1483429, or by visiting the “Investors” section at www.sparktx.com.
About Spark Therapeutics
At Spark Therapeutics, a fully integrated company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia and neurodegenerative diseases. We have successfully applied our technology in the first FDA-approved gene therapy in the U.S. for a genetic disease, and currently have three programs in clinical trials, including product candidates that have shown promising early results in patients with hemophilia. At Spark, we see the path to a world where no life is limited by genetic disease. For more information, visit www.sparktx.com, and follow us on Twitter and LinkedIn.
| Investor Contact: Ryan Asay [email protected] (215) 239-6424 | Media Contact: Monique da Silva [email protected] (215) 282-7470 |
